Cocrystal Pharma, Inc. (COCP)
| Market Cap | 51.66M |
| Revenue (ttm) | 510,000 |
| Net Income (ttm) | -11.99M |
| Shares Out | 97.47M |
| EPS (ttm) | -0.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 551,490 |
| Open | 0.550 |
| Previous Close | 0.553 |
| Day's Range | 0.501 - 0.565 |
| 52-Week Range | 0.500 - 3.460 |
| Beta | 0.62 |
| Analysts | Buy |
| Price Target | 4.50 (+749.1%) |
| Earnings Date | n/a |
About COCP
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for...
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for COCP stock is "Buy." The 12-month stock price forecast is 4.50, which is an increase of 749.06% from the latest price.
News
Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205
Response to pre-IND briefing package supports pathway to initiating a Phase 1 clinical study in 2022
Cocrystal's COVID-19 Antiviral Candidate Shows Potency Against Omicron Variant
Cocrystal Pharma Inc's (NASDAQ: COCP) COVID-19 antiviral candidate has shown antiviral potency against the omicron variant in vitro studies. The Company earlier confirmed that its protease inhibitors d...
Cocrystal Pharma's COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Again...
Antiviral activity now confirmed against SARS-CoV-2 and all variants of concern including Omicron, Delta, Alpha, Beta and Gamma
4 Biotech Penny Stocks to Watch With New Catalysts
These biotech penny stocks could be worth watching after recent announcements The post 4 Biotech Penny Stocks to Watch With New Catalysts appeared first on Penny Stocks to Buy, Picks, News and Informati...
Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Mark...
BOTHELL, Wash., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that President and interim CEO Sam Lee, Ph.D. and CFO and interim CEO Jam...
Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at ...
Unveils designs for Phase 1 and 2 stud ies with intranasal/pulmonary and oral SARS-CoV-2 protease inhibitors ; trial initiations expected in 2022
Cocrystal Pharma, Inc. (COCP) Reports Q3 Loss, Lags Revenue Estimates
Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Cocrystal Pharma, Inc. (COCP) Report Negative Q3 Earnings? What You Should Know
Cocrystal Pharma, Inc. (COCP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cocrystal Pharma's SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviru...
BOTHELL, Wash., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-...
Cocrystal Pharma Files To Start Human Trial For Protease Inhibitor In COVID-19
Cocrystal Pharma Inc (NASDAQ: COCP) has submitted a pre-Investigational New Drug (IND) briefing package to the FDA for its broad-spectrum protease inhibitor CDI-45205 in COVID-19. FDA's response is expe...
Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance o...
FDA 's response is expected to provide greater clarity and guidance on designing Phase 1 and Phase 2 clinical trials for CDI-45205
Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021
BOTHELL, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral...
Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of ...
BOTHELL, Wash., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral ...
5 Best Penny Stocks To Buy Right Now According To Insiders
5 Penny Stocks Insiders Are Buying Right Now The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Cocrystal Pharma, Inc. (COCP) Reports Q2 Loss, Misses Revenue Estimates
Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Cocrystal Pharma, Inc. (COCP) Report Negative Q2 Earnings? What You Should Know
Cocrystal Pharma, Inc. (COCP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cocrystal Pharma Stock Is Trading Higher After COVID-19 Candidate Shows Preclinical Activity Against Delta, Gamma Var...
Cocrystal Pharma Inc (NASDAQ: COCP) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma...
8 Hot Penny Stocks That You Should Add to Your July Watchlist
With July in full swing, here's 8 penny stocks that investors are watching right now The post 8 Hot Penny Stocks That You Should Add to Your July Watchlist appeared first on Penny Stocks to Buy, Picks, ...
Cocrystal Joins Russell Microcap® Index
BOTHELL, Wash., June 28, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral ...
Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A,...
BOTHELL, Wash., June 23, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral ...
7 Hot Penny Stocks to Watch That Are Trending Right Now
Which penny stocks are worth buying next month? Check these 7 out for your watchlist The post 7 Hot Penny Stocks to Watch That Are Trending Right Now appeared first on Penny Stocks to Buy, Picks, News a...
Cocrystal's (COCP) Antiviral CDI-45205 Effective Against COVID-19
Cocrystal (COCP) SARS-CoV-2 3CL protease inhibitor, CDI-45205, found to be effective in treating the original and two other variants of the COVID-19 virus. Shares up.
Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains
Cocrystal Pharma Inc (NASDAQ: COCP) has announced laboratory-based results for its lead preclinical SARS-CoV-2 3CL protease inhibitor, CDI-45205. A third-party laboratory contracted by Cocrystal conduct...
Cocrystal's Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Vari...
BOTHELL, Wash., June 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral ...
Cocrystal Pharma's Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online
BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral...